Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology

Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, recently shared on X:

“The TRAIN3 trial of MRI-guided TCHP (3, 6 or 9 cycles) is out in The Lancet Oncology. MRI identified patients with HR-/HER2+ breast cancer having pCR after only 3 cycles of TCHP. May it be MRI, PET, GEP, or ctDNA, the future of treatment for HER2+ eBC will be biomarker driven.”

Read further.
Source: Paolo Tarantino/X